- Home
- TOP vs KZR Comparison
TOP vs KZR Comparison
Compare TOP & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.15
Company Overview
Basic Information| Metric | TOP | KZR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 45.8M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TOP | KZR |
|---|---|---|
| Price | $1.06 | $6.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 40.5K | 30.6K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,355,086.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $3.53 |
| 52 Week High | $3.33 | $6.65 |
Technical Indicators
Market Signals| Indicator | TOP | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 44.40 |
| Support Level | $1.03 | $6.10 |
| Resistance Level | $1.15 | $6.29 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 33.33 | 21.21 |
Price Performance
Historical Comparison TOP
KZR
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.